The leading biologics & bioconjugates (ADCs, AOCs, RDCs) CDMO + CRO

Abzena Bristol

Abzena is a biopharmaceutical CDMO + CRO that provides fully integrated, tailored drug design, development & GMP manufacturing services spanning discovery through commercial.

Why Abzena? Quality Excellence

Let’s work together to keep moving medicine forward.

1400+ Lead Candidates Discovered & Designed - Abzena

1400+

Lead Candidates Discovered & Designed

100+ Production Cell Lines Developed - Abzena

100+

Production Cell Lines Developed

2000+ Bioconjugates Developed & 400+ ADCs Produced - Abzena

2000+

Bioconjugates Developed & 400+ ADCs Produced

 

Discover Our 20+ Years’ Scientific Expertise & Track Record

About Abzena

We enable you to bring life-changing medicines to patients in need. Leverage our extensive experience in complex biologics and bioconjugation development to move your idea forward.

Contact Us

Our Offering

Biologics

Accelerate your path to market with our range of advanced biologic services & solutions that move medicine forward.

Learn More

Bioconjugates (ADCs, AOCs, RDCs)

Accelerate your timeline to the clinic or the market with our expertise in complex chemistry and bioconjugation services.

Learn More

Complex Chemistry

We develop novel and improve synthetic routes for complex chemicals, cytotoxins, payloads, linkers, HPAPI and more.

Learn More

Moving Medicine Forward

We offer best-in-class bioconjugate and biologic CDMO + CRO services. Along with a highly detailed and personalized experience, when you partner with Abzena expect:

  • Access to Genuine Scientific & Technical Experts
  • Proactive Solutions for Streamlining Development
  • Diverse and Interconnected Teams
  • End-to-End Support Under One Organization

Abzena develops and implements fully integrated and tailored solutions that realize the full potential of your molecule. Our offering means that your bioconjugate or biologic programs can go from promise to product faster by providing:

  • Fully integrated early R&D through commercial capabilities
  • High-quality & trusted data that drives development
  • Streamlined regulatory support tailored to your program
Why Abzena?

We are advocates and partners for your success. We deploy the best biologic development technologies, shorten lead times, and implement effective risk mitigation strategies.

Discover Testimonials
“Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena’s expertise, cooperation, and support.”


Paul Jaminet

Paul Jaminet | Co-founder & CEO
Angiex

Explore customer testimonials
"Abzena has been crucial in advancing and validating our technology and programs. The team is very thoughtful, has strong troubleshooting skills and maintains a high standard in generating quality data with integrity. We highly recommend working with Abzena."

Shiva Bhowmik, PhD

Shiva Bhowmik, PhD | COO
TRIO Pharmaceuticals, Inc.

Explore customer testimonials
"We worked with the Abzena team for the design and the initial production of both the mAb and the antibody-chelator conjugate to support our R&D programs. We had a productive and valuable interaction with a highly skilled scientific team and we benefited from the flexibility of the services at this early stage of development."
Tina Bjørnlund Bønsdorff

Tina Bjørnlund Bønsdorff | CSO
Oncoinvent AS

Explore customer testimonials
"I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects."



David Jackson

David Jackson | Pharmaceutical Consultant & ADC Expert
DYJ Pharma Consulting

Explore customer testimonials

Latest Insights

Feature: Simplify & Secure Your Supply Chain

We are reacting to potential tariff changes – striving to proactively reshape our supply chain strategy.

Learn More

Whitepaper: Random Integration vs. Semi-Targeted Integration in Stable Cell Line Development

Abzena's CLD experts explore two primary approaches - random integration and semi-targeted (or transposase) integration.

Learn More

Case Study: CHO Cell Line Performance with 2G UNic® Technology

Discover our case study that assesses the impact of 2G UNic® vector technology on protein expression in CHO cell lines

Learn More
Let’s move medicine forward - Abzena

Let's move medicine forward

We enable you to bring life-changing medicines to patients in need faster. Let’s talk and move medicine forward.

Contact Us Download Brochure